CS
NEPH icon

Cannell & Spears’s Nephros NEPH Stock Holding History

Cannell & Spears’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.8K Hold
11,000
– – ﹤0.01% 420
2025
Q4 		$53.7K Buy
+11,000
New +$56.2K ﹤0.01% 409

Other funds holding NEPH

WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Cornerstone Capital Palo Alto, California $1B AUM 21.47% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Cannell & Spears's NEPH Position: Q1 2026 in Review

Cannell & Spears held its Nephros (NEPH) position steady in Q1 2026 at 11,000 shares worth $32.8K. The position accounts for ﹤0.01% of the portfolio, ranked #420.

Cannell & Spears first reported a position in NEPH in Q4 2025 and has held it in 2 quarters since. The position peaked at $53.7K in Q4 2025. 27 funds tracked by Wall St. Rank hold NEPH as of Q1 2026.

  • Cannell & Spears held 11,000 shares of Nephros worth $32.8K as of Q1 2026.
  • Cannell & Spears left its Nephros share count unchanged in Q1 2026.
  • Nephros made up ﹤0.01% of Cannell & Spears's portfolio in Q1 2026, its #420 holding.
  • Cannell & Spears first reported a position in Nephros in Q4 2025 and has held it in 2 quarters since.
  • Cannell & Spears's Nephros position peaked at $53.7K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Nephros as of Q1 2026.

Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.